Study Period Site Criteria for failure N Median Duration of ART (months) ART Regimen (%) ≥1 DRM
(%)
NNRTI
(%)
M184V
(%)
TAM
(%)
TAM ≥3
(%)
K65R
(%)
Ref
Aug 2011- Dec 2012 Rural clinics 1 ×  VL >1000 89 39.6 d4T/3TC/EFV (72)
d4T/3TC/LPVr (14)
ABC/3TC/EFV (9)
Other (6)
91.0 71.9 78.7 23.4 5.5 5.6 Pillay et al.
[47]
Aug 2008 to Jan 2010  Urban Hospital 1 ×  VL >1000 41 28.6 d4T/3TC/EFV (61) d4T/3TC/LPVr (15)
AZT/3TC/NVP (7)
Other (10)
85.4 78.0 70.7 58.5 39.0 7.3 Green et al.
[46]
2009 Urban Clinic 1 ×  VL >1000 1 ~22 D4T/3TC/RTV
AZT/3TC/LPVr
NA NA NA NA NA NA Murphy et al.
[45]
ART, antiretroviral therapy; N, number of patients genotyped; DRM, drug resistance mutation; TAM, thymidine analogue mutation; VL, viral load; NR, Not reported; NA, Not applicable; Ref, Reference
Table 3: Summary of acquired drug resistance studies in children treated with first-line antiretroviral therapy in KwaZulu-Natal, South Africa.